Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 5/20 | 0.35 |
| ▸ | TOP1 | P11387 | 2/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | CYCS | P99999 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12763748 | 0.95 | KDM4E (0.36) | KDM4ECASP1CASP7HSD17B10L3MBTL1 | |
| SCHEMBL10314951 | 0.91 | KDM4E (0.31) | KDM4ECASP1CASP7HSD17B10L3MBTL1 | |
| SCHEMBL1410106 | 0.88 | TERT (0.43) | KDM4ECASP1CASP7HSD17B10L3MBTL1 | |
| SCHEMBL1409926 | 0.80 | TOP1 (0.44) | TERTTOP1ABCG2CYCS | |
| SCHEMBL17018807 | 0.79 | KDM4E (0.38) | KDM4ECASP1CASP7HSD17B10L3MBTL1 | |
| SCHEMBL8001501 | 0.76 | TERT (0.37) | TERTTOP1CYCS | |
| SCHEMBL10314954 | 0.75 | TOP1 (0.43) | KDM4ECASP1CASP7HSD17B10L3MBTL1 | |
| SCHEMBL1410123 | 0.73 | STAT3 (0.50) | KDM4ECASP1CASP7HSD17B10L3MBTL1 | |
| SCHEMBL1410192 | 0.73 | TERT (0.46) | TERTTOP1ABCG2CYCS | |
| SCHEMBL7717047 | 0.73 | TERT (0.37) | KDM4ECASP1CASP7HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9289434-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150231150-A1 | SUBSTITUTED PORPHYRINS | AEOLUS PHARMACEUTICALS INC. | 2015-08-20 | — | — | US | disclosed |
| US-8946202-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140011794-A1 | SUBSTITUTED PORPHYRINS | Aeouls Sciences, Inc. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20110065679-A1 | Substituted Porphyrins | AEOLUS PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-7820644-B2 | Substituted porphyrins | Aelous Pharmaceuticals, Inc. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820644-B2 | Substituted porphyrins | Aelous Pharmaceuticals, Inc. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20070197496-A1 | for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2007-08-23 | — | — | US | disclosed |
| US-20070197496-A1 | for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2007-08-23 | — | — | US | disclosed |
| US-7189707-B2 | Substituted porphyrins | NATIONAL JEWISH MEDICAL RESEARCH CENTER (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189707-B2 | Substituted porphyrins | NATIONAL JEWISH MEDICAL RESEARCH CENTER (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231150-A1 | SUBSTITUTED PORPHYRINS | PPOX, GPX4, PRDX5 | KDM4E 3901/4885CASP1 823/4885CASP7 929/4885 |
| US-20110065679-A1 | Substituted Porphyrins | PPOX, GPX4, PRDX5 | KDM4E 3901/4885CASP1 823/4885CASP7 929/4885 |
| US-20140011794-A1 | SUBSTITUTED PORPHYRINS | PPOX, GPX4, PRDX5 | KDM4E 3901/4885CASP1 823/4885CASP7 929/4885 |
| US-20070197496-A1 | for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II | GPX4, LPO, TXNRD2 | KDM4E 4038/4885CASP1 1140/4885CASP7 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.